12-Week Study on the Efficacy of Two Serums in Improving Skin Aging and Tone

12-Week Serum Efficacy Study

This study aims to evaluate the anti-aging and skin tone improvement effects of two facial serums over a 12-week period. It was conducted at a single research center with a 2-week washout period followed by full-face application of the test products for 12 weeks.

A total of at least 120 healthy Chinese female participants aged 18 to 45 were enrolled and divided into two treatment groups:Each group included both early aging (18-29 years) and mature aging (30-45 years) subgroups, with at least 30 participants in each subgroup.

Study Overview

• Status: Completed
• Conditions: Facial Skin Aging and Dullness
• Intervention / Treatment: Other: Serum 1; Other: Serum 2

• Study Type: Interventional
• Enrollment (Actual): 120
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Shanghai, China
    • Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Chinese female aged 18-45 years (evenly split among Early aging [18-29 years] and Mature aging [30-45 years]).
2. All skin types (dry, normal, oily, or mixed).
3. Currently experiencing lack of radiance, roughness, dullness, and fine lines or wrinkles on facial skin as self-claimed.

4. Early aging group (18-29 years): Must present with corresponding severity for the attributes evaluated by Dermatologist, including:

   • Skin smoothness, radiance, dullness: grade between 2 and 6 (scale 0-9);
   • Size of acne marks (PIH): size ≥ 2;
   • Small folds on nasolabial zone: grade between 1 and 3 (Skin Aging Atlas, 0-6 scale, Page 56-57).

5. Mature aging group (30-45 years): Must present with corresponding severity for the attributes evaluated by Dermatologist, including:

   • Skin smoothness, radiance, dullness: grade between 4 and 6 (scale 0-9);
   • Small folds on nasolabial zone: grade between 1 and 4 (Skin Aging Atlas, 0-6 scale, Page 56-57);
   • Forehead wrinkles: grade ≥ 2 (Skin Aging Atlas, 0-8 scale, Page 32-33);
   • Crow's feet wrinkles: grade ≥ 2 (Skin Aging Atlas, 0-6 scale, Page 40-41).
6. Regular user of serum and sunscreen products.
7. Did not participate in any clinical test or cosmetic product test on skin within the last 3 months.
8. No exclusion by dermatologist due to other medical or dermatological reasons.
9. In general good health at the time of the study.
10. Willing and able to participate as evidenced by signing of informed consent and photo release form.
11. Must be willing to comply with all study protocol requirements (including using only the skincare products provided during the study and not taking topical or oral treatments such as retinol, hormones, or antioxidant health supplements).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Serum 1 Group; Participants in this arm applied Serum 1 (Fla#897183 329) to the full face twice daily for 12 weeks. The group included both early aging (18-29 years) and mature aging (30-45 years) subgroups.	Other: Serum 1; Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 1 group.
Experimental: Serum 2 Group; Participants in this arm applied Serum 2 (Fla#b50198) to the full face twice daily for 12 weeks. The group included both early aging (18-29 years) and mature aging (30-45 years) subgroups.	Other: Serum 2; Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 2 group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Dermatologist-Assessed Wrinkle Attributes	Crow's feet wrinkles, forehead wrinkles, global wrinkles, small folds on nasolabial zone and global fine lines will be evaluated by dermatologist.	from Baseline to Week 12
Self-assessment Questionnaire	Participants will complete a 5-point self-assessment questionnaire at Timm, T4w, T8w, and T12w, evaluating their perception of skin softness, smoothness, plumpness, elasticity, hydration, oil control, and visible aging signs. Ratings from 4 to 5 will be used to calculate "Top 2 box" percentage.	12 weeks
Change in Dermatologist-Assessed Skin Texture and Quality Attributes	Skin smoothness (visual), skin elasticity, skin softness, skin firmness, skin plumpness, cheek pores will be evaluated by dermatologist.	from Baseline to Week 12
Change in Dermatologist-Assessed Skin Tone Attributes	Skin radiance, skin translucency, skin pigmentation, skin fairness, skin tone evenness and skin dullness will be evaluated by dermatologist.	from Baseline to Week 12

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in Skin Hydration Measured by Corneometer	12 weeks
Change in Skin Elasticity Measured by Cutometer	12 weeks
Change in Transepidermal Water Loss (TEWL) Measured by Vapometer	12 weeks
Change in Facial Image-Based Skin Parameters Using VISIA-CR	12 weeks
Change in Cheek Skin Surface Condition Using VisioScan VC20	12 weeks

Collaborators and Investigators

• Sponsor: ChinaNorm

Study record dates

Study Major Dates

• Study Start (Actual): November 18, 2023
• Primary Completion (Actual): March 1, 2024
• Study Completion (Actual): March 22, 2024

Study Registration Dates

• First Submitted: August 20, 2025
• First Submitted That Met QC Criteria: September 3, 2025
• First Posted (Estimated): September 4, 2025

Study Record Updates

• Last Update Posted (Estimated): September 8, 2025
• Last Update Submitted That Met QC Criteria: September 4, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: C23005059

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No